
133 Molesworth Street
PO Box 5013
Wellington 6140
29 October 2025
New Zealand
T +64 4 496 2000
W www.medsafe.govt.nz
Erika Whittome
By email: [FYI request #32433 email]
Ref:
H2025073480
Tēnā koe Erika
Response to your request for official information
Thank you for your request under the Official Information Act 1982 (the Act) to the Ministry of
Health – Manatū Hauora (the Ministry) on 1 October 2025 for:
I note the Comirnaty product lists cholesterol as an ingredient in the "6.1 List of excipients"
1. Would you please provide the all the pharmacokinetics of the cholesterol ingredient in
Comirnaty?
2. I request the information on how this substance gets absorbed, distributed, metabolised
in, and excreted from the body.
3. What is the excretion and half-life of this particular cholesterol ingredient in the
Comirnaty injections from Pfizer/BioNTech?
All documents relating to the decision to approve Comirnaty as discovered by the Crown in the
Nga Kaitiaki Tuku Iho Medical Action Society v Minister of Health High Court proceedings have
been published on the Ministry’s website here:
www.health.govt.nz/system/files/2021-
10/h202106950_-_response.pdf. You were provided with a link to this information under your
previous response (H2025061333 refers). Distribution studies of ingredients (including
cholesterol) are included in non-clinical studies (refer to document 12).
As you were advised in your previous response, further non-clinical data relating to Comirnaty is
withheld under 9(2)(b)(ii) of the Act in this case, as its release would likely unreasonably prejudice
the commercial position of the person/third party who supplied the information. I have considered
the countervailing public interest in release in making this decision and consider that it does not
outweigh the need to withhold at this time.
If you wish to discuss any aspect of your request with us, including this decision, please feel free
to contact the OIA Services Team on:
[email address].
Under section 28(3) of the Act, you have the right to ask the Ombudsman to review any decisions
made under this request. The Ombudsman may be contacted by email at:
[email address] or by calling 0800 802 602.
Please note that this response, with your personal details removed, may be published on the
Ministry website at:
www.health.govt.nz/about-ministry/information-releases/responses-official-
information-act-requests.
Nāku noa, nā
Chris James
Group Manager
Medsafe